Jazz Pharmaceuticals Data to Showcase Ongoing Sleep Medicine Research at SLEEP 2019
Fourteen abstracts sponsored by Jazz Pharmaceuticals and one abstract from an investigator-sponsored trial focusing on sodium oxybate will be presented at SLEEP 2019 San Antonio from June 8-12, 2019.
“Jazz is committed to making meaningful strides in researching medicines that can improve the lives of people living with sleep disorders,” says Jed Black, MD, senior vice president, Sleep and CNS Medicine at Jazz Pharmaceuticals and adjunct professor, Stanford University Medical Center, Stanford Center for Sleep Sciences and Medicine, in a release. “There continue to be large unmet needs in these patient populations, and we are looking forward to presenting new data from our sleep portfolio, including our newest sleep medicine to be approved by FDA, solriamfetol.”
On March 20, 2019, Jazz announced that the US Food and Drug Administration (FDA) approved Sunosi (solriamfetol) to improve wakefulness in adult patients with excessive daytime sleepiness associated with narcolepsy or obstructive sleep apnea (OSA). Sunosi is expected to be commercially available in the United States following the final scheduling decision by the U.S. Drug Enforcement Administration (DEA), which is typically within 90 days of FDA approval.
Highlights at SLEEP will include the following poster presentations:
- Results from pooled analyses from 12-week randomized studies of solriamfetol for the treatment of excessive daytime sleepiness in patients with obstructive sleep apnea (OSA) or narcolepsy.
- Long-term effects of solriamfetol on quality of life in patients with excessive daytime sleepiness associated with narcolepsy or OSA.
- Treatment patterns among patients with narcolepsy treated with sodium oxybate.
- Physician prescribing patterns for patients with narcolepsy treated with sodium oxybate.
- Evaluation of cataplexy-free days in children/adolescents with narcolepsy with cataplexy treated with sodium oxybate.
The full list of Jazz-supported and related oral and poster presentations is as follows.
Solriamfetol Poster Presentations
Pooled Analyses from 12-Week Randomized, Controlled Studies of Solriamfetol in the Treatment Of Excessive Daytime Sleepiness In Participants With OSA Or Narcolepsy
June 9 / 5:15 p.m. – 7:15 p.m. / 0616 / Bridge Hall
Long-Term Effects of Solriamfetol on Quality of Life In Participants with Excessive Daytime Sleepiness Associated with Narcolepsy or Obstructive Sleep Apnea
June 9 / 5:15 p.m. – 7:15 p.m. / 0601 / Bridge Hall
Dose Titration of Solriamfetol in Participants with Obstructive Sleep Apnea (OSA) from a 6-Week Randomized-Withdrawal Trial
June 11 / 5:15 p.m. – 7:15 p.m. / 0570 / Bridge Hall
Weight Change Associated with Solriamfetol Treatment of Excessive Daytime Sleepiness in Participants with Narcolepsy or Obstructive Sleep Apnea
June 9 / 5:15 p.m. – 7:15 p.m. / 0618 / Bridge Hall
Solriamfetol Treatment of Excessive Daytime Sleepiness in Parkinson’s Disease: Results from a Phase 2 Proof-of-Concept Trial
June 9 / 5:15 p.m. – 7:15 p.m. / 0617 / Bridge Hall
Incidence and Duration of Common Adverse Events in a Solriamfetol (JZP-110) Phase 3 Study for Treatment of Excessive Daytime Sleepiness in Obstructive Sleep Apnea
June 11 / 5:15 p.m. – 7:15 p.m. / 0569 / Bridge Hall
Sodium Oxybate Presentations
Treatment Patterns among Patients with Narcolepsy Treated with Sodium Oxybate
Poster presentation: June 9 / 5:15 p.m. – 7:15 p.m. / 0604 / Bridge Hall
Oral presentation: June 11 / 10:30 a.m. – 12:30 p.m. / 0604 / Bridge Hall
Physician Prescribing Patterns for Patients with Narcolepsy Treated with Sodium Oxybate
June 9 / 5:15 p.m. – 7:15 p.m. / 0608 / Bridge Hall
Dosing, Titration, and Treatment Compliance to Sodium Oxybate Therapy in Pediatric Patients With Narcolepsy
June 9 / 5:15 p.m. – 7:15 p.m. / 0765 / Bridge Hall
Evaluation of Cataplexy-Free Days in Children/Adolescents with Narcolepsy with Cataplexy Treated with Sodium Oxybate
June 9 / 5:15 p.m. – 7:15 p.m. / 0766 / Bridge Hall
Long-Term Safety of Sodium Oxybate in Pediatric Narcolepsy with Cataplexy: Open-Label Continuation Post 1-Year of Treatment
Poster presentation: June 9 / 5:15 p.m. – 7:15 p.m. / 0767 / Bridge Hall
Oral presentation: June 11 / 10:30 a.m. – 12:30 p.m. / 0767 / Bridge Hall
Sodium Oxybate Dosing Utilization Patterns in the Nexus Narcolepsy Registry
June 9 / 5:15 p.m. – 7:15 p.m. / 0605 / Bridge Hall
Patient Survey Poster Presentation
Prevalence and Morbidity of Sleepiness in an Online Sleep Apnea Patient Cohort
June 11 / 5:15 p.m. – 7:15 p.m. / 0487 / Bridge Hall
Narcolepsy Prevalence Poster Presentation
Prevalence of Diagnosed Pediatric Narcolepsy in the United States
June 9 / 5:15 p.m. – 7:15 p.m. / 0761 / Bridge Hall
Investigator-sponsored Trial Focusing on Sodium Oxybate
Acute Total Sleep Deprivation Impairs the Ability to Manage Response Conflict
Poster Presentation: June 10 / 5:15 PM – 7:15 PM / 0213 / Bridge Hall
Oral Presentation: June 11 / 1:45 PM – 2:45 PM / 0213 / Bridge Hall
from Sleep Review http://www.sleepreviewmag.com/2019/05/jazz-research-sleep2019/